Sight Sciences Q2 FY26 net loss narrows 63% to $4.4 million; revenue rises 20% to $23.4 million

PUBT · 2d ago
Sight Sciences Q2 FY26 net loss narrows 63% to $4.4 million; revenue rises 20% to $23.4 million
  • Sight Sciences posted Q2 revenue of USD 23.4 million, up 20% year over year; net loss narrowed to USD 4.4 million, or USD 0.08 a share.
  • Interventional Glaucoma revenue rose 8% to USD 20.7 million on higher volumes; Interventional Dry Eye revenue climbed to USD 2.7 million from USD 0.3 million.
  • Gross margin rose 6.6 percentage points to 91% on a USD 1.4 million tariff-refund benefit; cash used totaled USD 5.2 million, including a USD 5.4 million litigation success fee.
  • Cash and cash equivalents ended June at USD 79.8 million; total operating expenses fell 11% to USD 25.3 million.
  • Raised full-year revenue guidance to USD 88 million-USD 92 million; cut non-GAAP adjusted operating expense outlook to USD 92 million-USD 94 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.